180 related articles for article (PubMed ID: 16796017)
1. The pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of monoclonal antibodies as PAI-1 inhibitors.
Gils A
Verh K Acad Geneeskd Belg; 2006; 68(3):179-98. PubMed ID: 16796017
[TBL] [Abstract][Full Text] [Related]
2. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors.
Gils A; Declerck PJ
Thromb Haemost; 2004 Mar; 91(3):425-37. PubMed ID: 14983217
[TBL] [Abstract][Full Text] [Related]
3. Use of mouse models to study plasminogen activator inhibitor-1.
Declerck PJ; Gils A; De Taeye B
Methods Enzymol; 2011; 499():77-104. PubMed ID: 21683250
[TBL] [Abstract][Full Text] [Related]
4. Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin.
Declerck PJ; Gils A
Semin Thromb Hemost; 2013 Jun; 39(4):356-64. PubMed ID: 23504606
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor-1.
Gils A; Declerck PJ
Curr Med Chem; 2004 Sep; 11(17):2323-34. PubMed ID: 15379715
[TBL] [Abstract][Full Text] [Related]
6. Recombinant plasminogen activator inhibitor type 1: a review of structural, functional, and biological aspects.
Reilly TM; Mousa SA; Seetharam R; Racanelli AL
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):73-81. PubMed ID: 8180342
[TBL] [Abstract][Full Text] [Related]
7. The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo.
Van De Craen B; Declerck PJ; Gils A
Thromb Res; 2012 Oct; 130(4):576-85. PubMed ID: 22801256
[TBL] [Abstract][Full Text] [Related]
8. [Plasminogen activator-inhibitor 1: biochemical, structural and functional studies].
Declerck P
Verh K Acad Geneeskd Belg; 1993; 55(5):457-73. PubMed ID: 8128782
[TBL] [Abstract][Full Text] [Related]
9. The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator.
van Meijer M; Stoop A; Smilde A; Preissner KT; van Zonneveld AJ; Pannekoek H
Thromb Haemost; 1997 Mar; 77(3):516-21. PubMed ID: 9066004
[TBL] [Abstract][Full Text] [Related]
10. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
Schroeck F; Arroyo de Prada N; Sperl S; Schmitt M; Viktor M
Biol Chem; 2002; 383(7-8):1143-9. PubMed ID: 12437099
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.
De Taeye B; Gils A; Vleugels N; Rabijns A; Declerck PJ
Biochem Biophys Res Commun; 2004 Aug; 321(3):746-51. PubMed ID: 15358169
[TBL] [Abstract][Full Text] [Related]
12. Characterization of recombinant rat plasminogen activator inhibitor-1 and development of immunological tools for its quantitation.
Ngo TH; Verheyen S; Knockaert I; Declerck PJ
J Pharm Belg; 1997; 52(4):165-6. PubMed ID: 9316343
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease.
Nordt TK; Peter K; Ruef J; Kübler W; Bode C
Thromb Haemost; 1999 Sep; 82 Suppl 1():14-8. PubMed ID: 10695479
[TBL] [Abstract][Full Text] [Related]
14. Modulation of sympathetic activity by tissue plasminogen activator is independent of plasminogen and urokinase.
Schaefer U; Vorlova S; Machida T; Melchor JP; Strickland S; Levi R
J Pharmacol Exp Ther; 2007 Jul; 322(1):265-73. PubMed ID: 17429057
[TBL] [Abstract][Full Text] [Related]
15. The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant?
De Taeye B; Gils A; Declerck PJ
Thromb Haemost; 2004 Nov; 92(5):898-924. PubMed ID: 15543316
[TBL] [Abstract][Full Text] [Related]
16. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.
Debrock S; Declerck PJ
Biochim Biophys Acta; 1997 Feb; 1337(2):257-66. PubMed ID: 9048903
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor type 1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via alpha(v)beta(5) integrin.
Takahashi T; Suzuki K; Ihara H; Mogami H; Kazui T; Urano T
Semin Thromb Hemost; 2005 Jun; 31(3):356-63. PubMed ID: 16052409
[TBL] [Abstract][Full Text] [Related]
19. Genetic architecture of tissue-type plasminogen activator and plasminogen activator inhibitor-1.
Asselbergs FW; Pattin K; Snieder H; Hillege HL; van Gilst WH; Moore JH
Semin Thromb Hemost; 2008 Sep; 34(6):562-8. PubMed ID: 19085655
[TBL] [Abstract][Full Text] [Related]
20. Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1.
Bijnens AP; Ngo TH; Gils A; Dewaele J; Knockaert I; Stassen JM; Declerck PJ
Thromb Haemost; 2001 May; 85(5):866-74. PubMed ID: 11372681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
